Cervical cancer marker detects high-risk cases
This article was originally published in Clinica
Matritech's NMP179 protein marker test for cervical cancer detected 92% of high-risk cases that had been identified as equivocal using traditional Pap tests, according to follow-up data from 259 women.
You may also be interested in...
Increased fines and penalties are on the cards for manufacturing facilities that fail to comply with proposed new requirements.
The biopharma sector is often accused of a being a slow-moving engine, but a look back over the last 20 years reveals that a lot has changed. In Vivo explores the history of high-impact M&A transactions in the industry between 1999 and 2019.
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.